By Michael Dabaie

 

Merck & Co. Inc. said the U.S. Food and Drug Administration granted Breakthrough Therapy designation to MK-6482 for certain patients with von Hippel-Lindau disease-associated renal cell Carcinoma.

The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with VHL-associated clear cell RCC.

Von Hippel-Lindau disease is a rare genetic disease. Patients with VHL disease are at risk for benign blood vessel tumors as well as several cancers, including RCC, Merck said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

July 29, 2020 09:20 ET (13:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Merck Charts.